Swiss National Bank purchased a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 26,400 shares of the company’s stock, valued at approximately $1,011,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Millennium Management LLC boosted its position in shares of Tyra Biosciences by 28.2% during the 1st quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock valued at $3,759,000 after purchasing an additional 89,024 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Tyra Biosciences by 21.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock worth $725,000 after purchasing an additional 13,896 shares during the last quarter. Woodline Partners LP bought a new stake in shares of Tyra Biosciences in the 1st quarter worth approximately $931,000. Jane Street Group LLC bought a new stake in shares of Tyra Biosciences in the 1st quarter worth approximately $324,000. Finally, Geode Capital Management LLC lifted its stake in Tyra Biosciences by 9.8% during the second quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock valued at $5,428,000 after purchasing an additional 50,836 shares during the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.
Tyra Biosciences Trading Down 3.6%
TYRA stock opened at $31.88 on Friday. Tyra Biosciences, Inc. has a one year low of $9.96 and a one year high of $40.65. The firm has a 50-day moving average of $30.48 and a two-hundred day moving average of $32.66. The firm has a market capitalization of $1.90 billion, a PE ratio of -14.62 and a beta of 0.76.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Guggenheim began coverage on shares of Tyra Biosciences in a report on Tuesday, April 14th. They set a “buy” rating and a $54.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. JonesTrading initiated coverage on Tyra Biosciences in a research report on Wednesday, June 17th. They set a “buy” rating and a $56.00 price objective for the company. Canaccord Genuity Group assumed coverage on Tyra Biosciences in a research note on Monday, April 6th. They set a “buy” rating and a $50.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $45.00 target price on shares of Tyra Biosciences in a report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Tyra Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.
Read Our Latest Stock Analysis on Tyra Biosciences
Tyra Biosciences Profile
Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.
The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.
Featured Articles
- Five stocks we like better than Tyra Biosciences
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Want to see what other hedge funds are holding TYRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report).
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
